At a glance
ClinicalIndex Comparison Record- ✓Aged 18 to 80 years
- ✓Dilated LV with EF ≤40% on echocardiography or CMR
- ✓Unexplained by pressure/volume overload, CAD, or systemic disease
- ✓If chemotherapy-induced: ≥2 years cancer-free and ≤30% recurrence risk at 5 years
- ✕CRT or ICD implantation in preceding 3 months
- ✕End-stage HF (ACCF/AHA Stage D) or terminal HF with life expectancy <12 months
- ✕Inotropic agents in preceding 1 month
- ✕Acute heart failure
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05774509Phase 1RecruitingUpdate OverdueUpdated 33mo ago · Completion was 10mo agoTreatment of Non-ischemic Dilated Cardiomyopathies by Intravenous Infusions of the Extracellular Vesicle-Enriched Secretome of Cardiovascular Progenitor Cells
In Brief
A Phase 1 clinical trial evaluating Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells for Heart Failure With Reduced Ejection Fraction. Currently recruiting, targeting 12 participants across 1 site.
Signals
Detailed Summary
The goal of this clinical trial is to assess the safety and efficacy of three intravenous injections of the extracellulat vesicle-enriched secretome of cardiovascular progenitor cells in severely symptomatic patients with drug-refractory left ventricular (LV) dysfunction secondary to non-ischemic dilated cardiomyopathy. The main questions it aims to answer are: * Are these repeated injections safe and well tolerated? * Do they improve cardiac function and, if yes, to what extent?
Study Details
Timeline
Interventions
Repeated (X3) intravenous infusions of the extracellular vesicle-enriched secretome of cardiovascular progenitor cells (differentiated from human induced pluripotent stem cells)